ArticleInfection control and hospital epidemiology2026
Active surveillance cultures and cohorting for carbapenem-resistant
Article in Infection control and hospital epidemiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCarbapenem-resistant
methodsA retrospective study was conducted at a 515-bed university hospital in Israel (January 2016-August 2025; 2020-2021 excluded). Screening of high-risk patients commenced in January 2023 utilizing four-limb skin sponges, with comprehensive implementation and patient cohorting initiated in July 2023. Outcomes were CRAB present on admission (POA) and hospital-acquired CRAB (overall and clinical subsets). We fit quasi-Poisson ITS models (January 2022-August 2025) with log link and exposure offsets (admissions for POA; hospital days for acquired); total counts were modeled with negative binomial regression. Cases averted were estimated with rate-based and ITS counterfactuals.
resultsPOA detection increased markedly after screening implementation (median 0.72 to 2.98 per 1,000 admissions), revealing a large reservoir of admission carriage. Overall hospital-acquired CRAB rates showed no sustained decline. In contrast, hospital-acquired clinical-CRAB fell substantially after July 2023 (mean 3.93 to 0.97 per 10,000 hospital-days), with a marked post-intervention level reduction in the ITS model (Incidence-rate ratio (IRR) 0.224, 95% CI 0.071-0.072,
conclusionsIn an endemic setting, hospital-wide ASC targeting high-risk patients unmasked extensive admission carriage and, combined with cohorting and other IPC measures, was associated with a substantial reduction in acquired clinical-CRAB cases.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.